Avalyn Pharma (NASDAQ:AVLN) Upgraded at Raymond James Financial

Key Points

• Raymond James upgraded Avalyn Pharma to “moderate buy,” while analyst sentiment remains mixed; MarketBeat reports an overall “Moderate Buy” rating and an average price target of $60.
• AVLN shares opened at $28.13, below their 50-day moving average of $33.49, with a market capitalization of approximately $1.25 billion. The stock has traded between $24.15 and $40.17 over the past year.
• Avalyn reported a quarterly loss of $0.98 per share, beating analysts’ $1.03 loss estimate. Several institutional investors, including Montanova Capital and Braidwell, recently established sizable positions in the company.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was upgraded by equities researchers at Raymond James Financial to a "moderate buy" rating in a research report issued on Friday, Zacks reports.

Other research analysts also recently issued research reports about the company. Wall Street Zen downgraded Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th. Morgan Stanley lifted their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Finally, Weiss Ratings initiated coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They set a "sell (d+)" rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $60.00.

Avalyn Pharma Price Performance

Shares of AVLN opened at $28.13 on Friday. The company's 50 day moving average price is $33.49. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma has a one year low of $24.15 and a one year high of $40.17. The firm has a market capitalization of $1.25 billion and a P/E ratio of -1.23.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.05. On average, analysts expect that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.

Institutional Trading of Avalyn Pharma

A number of hedge funds have recently made changes to their positions in AVLN. Montanova Capital LLC acquired a new position in shares of Avalyn Pharma in the second quarter valued at approximately $82,402,000. Braidwell LP acquired a new stake in Avalyn Pharma during the 2nd quarter worth approximately $26,382,000. State Street Corp bought a new stake in Avalyn Pharma during the 2nd quarter worth approximately $10,501,000. Finally, Bank of New York Mellon Corp acquired a new position in Avalyn Pharma in the 2nd quarter valued at approximately $1,321,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company's primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn's lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company's development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.